Nephrocare Health Services Limited has announced its participation in an upcoming investor conference, informing both BSE Limited and National Stock Exchange of India Limited about the scheduled engagement with analysts and institutional investors.

Conference Details

The company will participate in the IIFL Conference scheduled for February 24, 2026, in Mumbai. The engagement is structured to facilitate both group discussions and individual one-on-one meetings with market participants.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. Company Secretary and Compliance Officer Kishore Kathri signed the disclosure on February 18, 2026.

The company has specifically stated that all discussions during the investor interactions will be based exclusively on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during these meetings, ensuring compliance with regulatory requirements.

Additional Information

Nephrocare Health Services Limited, formerly known as Nephrocare Health Services Private Limited, trades on BSE with scrip code 544647 and on NSE with the symbol NEPHROPLUS. The company has noted that schedule changes may occur due to exigencies on the part of either the host or the company. The disclosure is also available on the company's official website at www.nephroplus.com .

Nephrocare Health Services Limited has announced a strategic asset acquisition in the Philippines through its subsidiary company. The healthcare services provider disclosed the transaction details to stock exchanges as part of its regulatory compliance obligations.

Asset Acquisition Details

Nephrocare Health Care Services Philippines Inc., a step-down wholly-owned subsidiary of Nephrocare Health Services Limited, has entered into an Asset Transfer Agreement with Laurel Kidney Care Dialysis Centre Inc. The agreement, dated February 12, 2026, involves the acquisition of identified assets relating to a dialysis center located at Laurel, Batangas, Philippines.

Regulatory Compliance and Disclosure

The company made the disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The information was communicated to both BSE Limited (Scrip Code: 544647) and National Stock Exchange of India Limited (Scrip Symbol: NEPHROPLUS).

Transaction Structure and Terms

The asset acquisition focuses specifically on dialysis center operations, aligning with Nephrocare's core healthcare services business. Key aspects of the transaction include:

• Purpose: Acquisition of dialysis center assets through Asset Transfer Agreement
• Special Rights: No special rights are associated with the agreement
• Related Party Status: The transaction does not fall within related party transactions
• Relationship: The seller is not related to the promoter/promoter group, while the purchaser is a step-down wholly-owned subsidiary

Corporate Governance

The disclosure was signed by Kishore Kathri, Company Secretary & Compliance Officer (ICSI M. No. F9895), ensuring proper corporate governance protocols were followed. The company has also made the information available on its official website at www.nephroplus.com , maintaining transparency with stakeholders.

This acquisition represents Nephrocare's continued expansion in the Philippines market, strengthening its dialysis care services network in the region through strategic asset acquisitions.